2,674 reports of this reaction
1.8% of all DOCETAXEL reports
#13 most reported adverse reaction
MALIGNANT NEOPLASM PROGRESSION is the #13 most commonly reported adverse reaction for DOCETAXEL, manufactured by Avyxa Pharma, LLC. There are 2,674 FDA adverse event reports linking DOCETAXEL to MALIGNANT NEOPLASM PROGRESSION. This represents approximately 1.8% of all 152,097 adverse event reports for this drug.
Patients taking DOCETAXEL who experience malignant neoplasm progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MALIGNANT NEOPLASM PROGRESSION is a less commonly reported adverse event for DOCETAXEL, but still significant enough to appear in the safety profile.
In addition to malignant neoplasm progression, the following adverse reactions have been reported for DOCETAXEL:
The following drugs have also been linked to malignant neoplasm progression in FDA adverse event reports:
MALIGNANT NEOPLASM PROGRESSION has been reported as an adverse event in 2,674 FDA reports for DOCETAXEL. This does not prove causation, but indicates an association observed in post-market surveillance data.
MALIGNANT NEOPLASM PROGRESSION accounts for approximately 1.8% of all adverse event reports for DOCETAXEL, making it a notable side effect.
If you experience malignant neoplasm progression while taking DOCETAXEL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.